key: cord-1048105-r5x2c5n6
authors: Abu-Raddad, Laith J; Chemaitelly, Hiam; Malek, Joel A; Ahmed, Ayeda A; Mohamoud, Yasmin A; Younuskunju, Shameem; Ayoub, Houssein H; Al Kanaani, Zaina; Al Khal, Abdullatif; Al Kuwari, Einas; Butt, Adeel A; Coyle, Peter; Jeremijenko, Andrew; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Shaik, Riyazuddin Mohammad; Rahim, Hanan F Abdul; Yassine, Hadi M; Al Kuwari, Mohamed G; Al Romaihi, Hamad Eid; Al-Thani, Mohamed H; Bertollini, Roberto
title: Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting
date: 2020-12-14
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1846
sha: 1dd820b6d057ddbd77d7b9e22e32ecf2e395cc54
doc_id: 1048105
cord_uid: r5x2c5n6

BACKGROUND: Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We assessed risk and incidence rate of documented SARS-CoV-2 reinfection in a cohort of laboratory-confirmed cases in Qatar. METHODS: All SARS-CoV-2 laboratory-confirmed cases with at least one PCR positive swab that is ≥45 days after a first-positive swab were individually investigated for evidence of reinfection, and classified as showing strong, good, some, or weak/no evidence for reinfection. Viral genome sequencing of the paired first-positive and reinfection viral specimens was conducted to confirm reinfection. Risk and incidence rate of reinfection were estimated. RESULTS: Out of 133,266 laboratory-confirmed SARS-CoV-2 cases, 243 persons (0.18%) had at least one subsequent positive swab ≥45 days after the first-positive swab. Of these, 54 cases (22.2%) had strong or good evidence for reinfection. Median time between first and reinfection swab was 64.5 days (range: 45-129). Twenty-three of the 54 cases (42.6%) were diagnosed at a health facility suggesting presence of symptoms, while 31 (57.4%) were identified incidentally through random testing campaigns/surveys or contact tracing. Only one person was hospitalized at time of reinfection, but was discharged the next day. No deaths were recorded. Viral genome sequencing confirmed four reinfections out of 12 cases with available genetic evidence. Reinfection risk was estimated at 0.02% (95% CI: 0.01-0.02%) and reinfection incidence rate at 0.36 (95% CI: 0.28-0.47) per 10,000 person-weeks. CONCLUSIONS: SARS-CoV-2 reinfection can occur but is a rare phenomenon suggestive of protective immunity against reinfection that lasts for at least a few months post primary infection.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading around the globe causing severe disruptions to social and economic activities [1] [2] [3] . Qatar, a peninsula in the Arabian Gulf region with a diverse population of 2.8 million [4, 5] , has experienced a large epidemic with one of the highest laboratory-confirmed rates of infection at >60,000 infections per million population [6] [7] [8] . Antibody testing and mathematical modeling indicated that about half of the population has already been infected [6, [8] [9] [10] [11] [12] .

The intensity of the epidemic with a high risk of re-exposure to the infection, as well as the availability of a centralized data-capture system of all laboratory-confirmed infections, provided an opportunity to epidemiologically assess the presence and incidence of reinfections; a poorly-understood feature of SARS-CoV-2 epidemiology whose elucidation is critical to inform global response, timing and intensity of future cycles, and impact and durability of potential vaccines [13] [14] [15] [16] .

Our aim was to assess the risk and incidence rate of documented reinfection in a cohort of 133,266 SARS-CoV-2 laboratory-confirmed infected persons. Since the relevant underlying question is whether risk of reinfection is appreciable or not, we implemented a conservative epidemiological approach for assessing documented reinfections, that is prone to overestimate rather than underestimate risk of reinfection. However, we also conducted sensitivity analyses implementing more stringent criteria for assessing reinfection. We further performed viral genome sequencing to confirm the reinfections. [17] , which is assessed through individual chart reviews by trained medical personnel. Recently, data on serological testing for antibody on residual blood specimens collected for routine clinical care from attendees at HMC were also incorporated [6, 10] .

All PCR testing was conducted at HMC Central Laboratory or at Sidra Medicine Laboratory, following standardized protocols. Nasopharyngeal and/or oropharyngeal swabs (Huachenyang Technology, China) were collected and placed in Universal Transport Medium (UTM). Aliquots of UTM were: extracted on the QIAsymphony platform (QIAGEN, USA) and tested with real-time reverse-transcription PCR (RT-qPCR) using TaqPath™ COVID-19 Combo Kit (100% sensitivity and specificity [18] ; Thermo Fisher Scientific, USA) on ABI 7500 FAST (Thermo Fisher, USA); extracted using a custom protocol [19] on Hamilton Microlab STAR (Hamilton, USA) and tested using AccuPower SARS-CoV-2 Real-Time RT-PCR Kit (100% sensitivity and specificity [20] ; Bioneer, Korea) on ABI 7500 FAST; or loaded directly to Roche cobas® 6800 system and A c c e p t e d M a n u s c r i p t 5 assayed with cobas® SARS-CoV-2 Test (95% sensitivity, 100% specificity [21] ; Roche, Switzerland). The first assay targets the virus' S, N, and ORF1ab regions; the second targets the virus' RdRp and E-gene regions; and the third targets the ORF1ab and E-gene regions.

Serological testing was performed using Roche Elecsys ® Anti-SARS-CoV-2 (99.5% sensitivity [22] , 99.8% specificity [22, 23] ; Roche, Switzerland), an electrochemiluminescence immunoassay that uses a recombinant protein representing the nucleocapsid (N) antigen for determination of antibodies against SARS-CoV-2. Qualitative anti-SARS-CoV-2 results were generated following the manufacturer's instructions (reactive: cutoff index for optical density ≥1.0 vs. non-reactive: cutoff index <1.0).

All SARS-CoV-2 laboratory-confirmed cases with at least one PCR positive swab that is ≥45 days after a first-positive swab were considered as suspected cases of reinfection. The 45-day cutoff was informed by data from observational cohorts of SARS-CoV-2 infected persons [24, 25] , and was set to account for the duration of prolonged PCR positivity of several weeks in these patients. Cutoff determination was further informed by the distribution of the time difference between the first-positive swab and subsequent positive swabs among SARS-CoV-2 cases with multiple swabs (Figure 1 ). The tail of this distribution indicates that a cutoff of 45 days (at the 99 th percentile) provides an appropriate mark for defining the end of prolonged PCR positivity: a subsequent positive swab within 45 days of the first-positive swab is likely to reflect prolonged PCR positivity (due to non-viable virus fragments) rather than reinfection, and thus should not be included in analysis.

A c c e p t e d M a n u s c r i p t 6

Suspected cases of reinfection, that is cases fitting above indicated inclusion criteria, were classified as showing either strong evidence, good evidence, some evidence, or weak (or no) evidence for reinfection (Box 1). Classification was based on holistic quantitative and qualitative criteria applied to each investigated case. Criteria included the pattern and magnitude of the change in PCR cycle threshold (Ct) value across repeated swabs, time interval between subsequent swabs, PCR testing site (such as outpatients at primary care, hospital emergency, or inpatient hospitalization), purpose of PCR testing (such as appearance of symptoms, contact tracing, or survey/testing campaign), age, history of COVID-19-related hospital admission, and case severity per WHO classification [17] . Shorter durations bordering the 45-day cutoff with Ct values ≥30 and no contextual evidence supporting the status of "reinfection" were indicative of some evidence for reinfection, but not strong nor good evidence for reinfection, as they are more likely to reflect the long tail of the prolonged PCR positivity distribution ( Figure 1 ) [24, 25] . Age ≥70 years, repeated swabs A c c e p t e d M a n u s c r i p t 7 on hospitalized patients, and severe or critical WHO disease classifications were considered as contextual factors indicative of poor control of the first infection rather than reinfection.

Cases that had such contextual factors (and implicitly did not fit the criteria of strong, good, or some evidence for reinfection) were considered to have weak (or no) evidence for reinfection.

Of note that hospitalized COVID-19 cases often had multiple subsequent swabs administered to them as part of clinical care, and repeated swabbing was standard earlier in the epidemic, as the criteria for discharge from an isolation facility required at least two subsequent PCR negative swabs. This was changed later to a time-based criteria per updated WHO recommendation [26] .

Documented reinfection risk was assessed by quantifying the proportion of cases with strong or good evidence for reinfection out of all laboratory-confirmed SARS-CoV-2 cases that were diagnosed ≥45 days from end-of-study censoring. Incidence rate of documented reinfection was calculated by dividing the number of cases with strong or good evidence by the number of person-weeks contributed by all laboratory-confirmed cases who had their first-positive swab ≥45 days before day of analysis. The follow-up person-time was calculated starting from 45 days after the first-positive swab and up to the reinfection swab, all-cause death, or end-of-study censoring.

Since we implemented a conservative approach prone to overestimate risk of documented reinfection, several sensitivity analyses were conducted implementing more stringent criteria for assessing reinfection: 1) exclusion of cases where the Ct value for the first and/or subsequent positive swab was unknown or with a value ≥35 (to exclude potential PCR false-A c c e p t e d M a n u s c r i p t 8 positive cases), 2) changing the ≥45-day cutoff to a ≥60-day cutoff to further exclude potential cases of long-term prolonged PCR positivity, and (most stringent) 3) setting definition of recent active infection at Ct cutoff value of <25 (instead of <30) and excluding any suspected reinfection case with Ct >25.

Viral genome sequencing was conducted on retrieved paired samples of the first-positive swab and reinfection swab for patients with strong or good evidence for reinfection as confirmatory analysis. Further details about the viral genome sequencing methods can be found in Supplementary Text S1.

Study was approved by HMC and Weill Cornell Medicine-Qatar Institutional Review Boards. Table 1 shows the characteristics of the 54 cases classified as showing strong or good evidence for reinfection. Almost all cases were males, but this reflects the focus of the epidemic in craft and manual workers [6] . Median age was 33 years (range: Nine of the 54 cases showing strong or good evidence for reinfection were hospitalized at any time. However, all but one occurred following the primary infection-only one hospitalization occurred at time of reinfection but the patient was discharged the next day.

Most hospitalizations occurred for isolation or initial assessment purposes as cases had no or minimal symptoms. Only one case had sufficient symptoms to warrant an infection severity assessment (during primary infection), but was classified with "mild" severity per WHO classification. No deaths were recorded. Of note that the vast majority of infections in Qatar occurred in young and healthy men and had low severity [6, 12] . Results of sensitivity analyses can be found in Supplementary Table S2 . In these analyses, the estimate for the risk of reinfection ranged between 0.02% (95% CI: 0.01-0.03) and 0.03% (95% CI: 0.02-0.04), while that for the incidence rate of reinfection ranged between 0.38 (95% CI: 0.24-0.60) and 1.06 (95% CI: 0.75-1.50) per 10,000 person-weeks. Although these sensitivity analyses confirmed our results, they suggested overestimation of the already low risk of reinfection.

Paired specimens of the first-positive and reinfection swabs could be retrieved for 23 out of the 54 cases with strong or good evidence for reinfection. Table 2 There was insufficient evidence to warrant interpretation for 11 pairs because of low genome quality. For six pairs, there were one to several changes of allele frequency indicative at best of a shifting balance of quasi-species, and thus no evidence for reinfection. For two pairs, remarkably, there was conclusive evidence for no reinfection as both genomes were of high quality yet no differences were found. For both patients, Ct was <25 for the first-positive and reinfection swabs indicating persistent active infection (Table 1) . These two cases were also sero-positive (Table 1) .

A c c e p t e d M a n u s c r i p t 11 Meanwhile, for two pairs, there was conclusive evidence for reinfection with multiple changes of allele frequency and presence of the D614G mutation (23403bp A>G)-a variant that appeared and expanded replacing the original D614 form [27, 28] . Also for two pairs, and although one of the genomes was of inferior quality, there was sufficient evidence for differences including the presence of the D614G mutation, thereby rendering evidence for reinfection. Three out of these four cases with viral genome sequencing confirmation of reinfection were classified above (epidemiological criteria) as having strong evidence for reinfection, with the fourth classified as having good evidence (Table 1 ). Antibody test result was available for one case at time of reinfection, and the individual was sero-negative.

In sum, for the 12 cases where viral genome sequencing evidence was available, four cases were confirmed as reinfections, a confirmation rate of 33.3%. Applying this rate to the aboveestimated reinfection metrics yielded risk of documented reinfection of 0.02% (95% CI: 0.01-0.02%) and incidence rate of reinfection of 0.36 (95% CI: 0.28-0.47) per 10,000 personweeks.

Results indicate, employing several analyses and sensitivity analyses, conclusive evidence for presence of reinfections in the SARS-CoV-2 epidemic of Qatar, but the risk for documented reinfection was very rare at about 2 reinfections per 10,000 infected persons. This finding is striking as the epidemic in Qatar has been intense with half of the population estimated to have been infected [6, [8] [9] [10] [11] [12] . Considering the strength of the force of infection, estimated at a daily probability of infection exceeding 1% at the epidemic peak around May 20 [6] , it is all but certain that a significant proportion of the population has been repeatedly exposed to the infection, but such re-exposures hardly led to any documentable reinfections.

A c c e p t e d M a n u s c r i p t 12 Indeed, of all epidemiologically-identified reinfections, nearly two-thirds (57%) were discovered accidentally, either through random testing campaigns/surveys or through contact tracing. None were severe, critical, or fatal; all reinfections were asymptomatic or with minimal or mild symptoms. These findings may suggest that most infected persons appear to develop immunity against reinfection that lasts for at least few months, and that reinfections (if they occur) are well tolerated and no more symptomatic than primary infections. Further follow up of this cohort of infected persons over time may allow elucidation of potential effects of waning of immunity.

Other lines of evidence for this cohort also support this conclusion. Among 2,559 PCR positive persons where an antibody test outcome was available [6] , and where the firstpositive PCR test was conducted >3 weeks before the serology test to accommodate for the delay in development of detectable antibodies following onset of infection [24, 25] , 91.7% were antibody positive [6] . The high antibody positivity was also stable for over three months [6] , as described elsewhere [14, 25] . The epidemic curve in Qatar was further characterized by rapid growth followed by rapid decline [6, 8, 12] , at a time when levels of social and physical distancing restrictions were fairly stable. This points to susceptibles-infectedrecovered "SIR" epidemic dynamics with most infections eliciting immunity against reinfection.

This assessment has limitations. We assessed risk of only documented reinfections, but other reinfections could have occurred but went undocumented, perhaps because of minimal/mild or no symptoms. It is also possible that with the primed immune system following primary infection, reinfections could be milder and shorter [15] . A recent nationwide populationbased survey in Qatar estimated that only 9.3% (95% CI: 7.9-11.0%) of those antibody positive had a prior documented laboratory-confirmed infection [9] , suggesting that undocumented infections (or reinfections) could possibly be ten-fold higher than documented A c c e p t e d M a n u s c r i p t 13 infections (or reinfections). This finding indicates that incidence rate of both documented and undocumented reinfections may add up to perhaps ~10 per 10,000 person-weeks. Meanwhile, a recent mathematical modeling study estimated the incidence rate of infection in Qatar at the time of the present study, including both documented and undocumented infections, at ~200 per 10,000 person-weeks [8] . Comparing these incidence rates suggest that the "efficacy" of natural infection against reinfection is around 1 10 200 95%

 . Viral genome sequencing analysis was possible for only a subset of reinfections. Antibody testing outcomes were also available for only a number of cases, limiting use and inferences of the link between antibody status and risk of reinfection. Of note that for one of the genetically-confirmed reinfections the antibody test result was available but was seronegative (Table 1) , just as the Hong Kong reinfected patient [29] .

In conclusion, SARS-CoV-2 reinfection appears to be a rare phenomenon. This may suggest that immunity develops after the primary infection and lasts for at least few months, and that immunity may protect against reinfection.

A c c e p t e d M a n u s c r i p t 14

We 

We declare no competing interests. Suspected cases of SARS-CoV-2 reinfection: all laboratory-confirmed cases with at least one polymerase chain reaction (PCR) positive swab that is ≥45 days after a first-positive swab.

Strong evidence for reinfection: individuals having positive swabs with PCR cycle threshold (Ct) value <30 at least 45 days after the first-positive swab. No contextual evidence supporting poor control of first infection such as age ≥70 years, repeated swabs on hospitalized patients, and severe or critical World Health Organization disease classifications.

Good evidence for reinfection: individuals having positive swabs with PCR Ct value ≥30 at least 45 days after the first-positive swab, but where PCR positivity was associated with contextual evidence supporting the status of reinfection:

 Appearance of symptoms (often as proxied by being diagnosed at a health facility)

 Infection diagnosis through contact tracing (indicating recent exposure to an infected person)

 Lower Ct value compared to last positive swab (indicating increasing viral load)

 Irregular and spaced-out pattern for repeated swabbing (to exclude cases under clinical management that are indicative of poor control of first infection).

No contextual evidence supporting poor control of first infection such as age ≥70 years, repeated swabs on hospitalized patients, and severe or critical World Health Organization disease classifications.

Some evidence for reinfection: individuals having positive swabs with PCR Ct value ≥30 at least 45 days after the first-positive swab, but typically bordering the cutoff of 45 days. PCR positivity was not associated with evidence supporting the status of reinfection (listed above).

Weak evidence for reinfection: individuals having swabs with PCR Ct value ≥30 at least 45 days after the firstpositive swab, but typically bordering the cutoff of 45 days. PCR positivity was associated with contextual evidence indicative of poor infection control of the first infection rather than reinfection (such as age ≥70 years, repeated swabs on hospitalized patients, and severe or critical World Health Organization disease classifications).

M a n u s c r i p t 19 FIGURE LEGENDS Figure 1 . Distribution of the time difference between the first swab and subsequent swabs among all laboratory-confirmed SARS-CoV-2 cases with more than one positive swab. The cutoff of 45 days was at the 99 th percentile, and thus provides an appropriate mark for defining the end of the prolonged polymerase chain reaction (PCR) positivity. 

WHO Director-General's opening remarks at the media briefing on COVID-19 -11

How two tests can help contain COVID-19 and revive the economy

A third of the global population is on coronavirus lockdown

Planning and Statistics Authority-State of Qatar. The Simplified Census of Population, Housing & Establishments

Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic

Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar

Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to

Seroprevalence of SARS-CoV-2 infection in the craft and manual worker population of Qatar

Seroprevalence of SARS-CoV-2 infection in the urban population of Qatar

Evidence for and level of herd immunity against SARS-CoV-2 infection: the ten-community study

SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection

Epidemiological impact of SARS-CoV-2 vaccination: Mathematical modeling analyses

Clinical management of COVID-19

TaqPath™ COVID-19 CE-IVD RT-PCR Kit instructions for use

High-throughput extraction of SARS-CoV-2 RNA from nasopharyngeal swabs using solid-phase reverse immobilization beads

Molecular and Serological Tests for COVID-19 a Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics

Cobas® SARS-CoV-2: Qualitative assay for use on the cobas® 6800/8800 Systems

Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2

Roche's COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark

Interpreting Diagnostic Tests for SARS-CoV-2

Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study

World Health Organization. Criteria for releasing COVID-19 patients from isolation

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Making Sense of Mutation: What D614G Means for the COVID-19 Pandemic Remains Unclear

COVID-19 re-infection by a phylogenetically distinct SARScoronavirus-2 strain confirmed by whole genome sequencing

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 20 A c c e p t e d M a n u s c r i p t